ENTX

Entera Bio Ltd. [ENTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ENTX Stock Summary

Top 10 Correlated ETFs

ENTX

Top 10 Correlated Stocks

ENTX

In the News

ENTX Financial details

Company Rating
-
Market Cap
105.73M
Income
-4.47M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-3.85
Forward P/E
-
PEG
0.58
P/S
1564.19
P/B
3.51
P/C
-
P/FCF
-3.26
Quick Ratio
3.74
Current Ratio
3.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
-31.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.2%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-18.64%
-
-
-
-
SMA20
-27.21%
SMA50
15.05%
SMA100
9.74%
Inst Own
-
Inst Trans
-
ROA
-66%
ROE
-63%
ROC
-0.85%
Gross Margin
-15757%
Oper. Margin
-39800%
Profit Margin
-40629%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.52-3.35
52W High
-
52W Low
-
RSI
40.39
Rel Volume
0.5
Avg Volume
182.6K
Volume
91.33K
Perf Week
5.1%
Perf Month
-23.23%
Perf Quarter
10.46%
Perf Half Y
3.1%
-
-
-
-
Beta
1.713
-
-
Volatility
0.04%, 0.34%
Prev Close
-2.04%
Price
2.165
Change
0.23%

Something similar

Top by Market Cap
DHR-PB
CMC.DE
AVGO
1YD.DE
NVDA
Top Correlated ETFs
KSA
FLSA
LABD
SPCX
9401.SR
Top Correlated Stocks
QIIWI.ST
AFGC
ZS
ASTRAMICRO.NS
FUBO
Similar Market Cap
0886.HK
CPHC
2159.HK
UIM3.DE
XDUH.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 182.6K
  • Market Capitalization 105.73M
  • Employee 17
  • CEO Ms. Miranda J. Toledano M.B.A.
  • Headquarters Jerusalem,IL
  • IPO Date 2018-06-28
  • Website https://www.enterabio.com

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.